Funder
GlaxoSmithKline
National Health and Medical Research Council
Memorial Sloan-Kettering Cancer Center
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Biology,Hematology
Reference31 articles.
1. Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii65–71.
2. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454–63.
https://doi.org/10.1200/JCO.2004.06.132
.
3. Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer. 2009;101(10):1717–23.
https://doi.org/10.1038/sj.bjc.6605366
.
4. European Medicines Agency. Votrient (pazopanib) authorisation details. 2010.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001141/human_med_001337.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true
Accessed 12 May 2018.
5. United States Food and Drug Administration. Pazopanib [approval notice]. 2009. Available at:
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022465s000ltr.pdf
.